Save time and jump to the most important pieces.
| Company | Date | Price Target | Rating | Analyst |
|---|---|---|---|---|
| 11/20/2024 | Sell → Neutral | UBS | ||
| 11/6/2024 | Sell → Hold | Deutsche Bank | ||
| 9/13/2024 | Hold → Sell | Deutsche Bank | ||
| 5/30/2024 | $97.00 | Buy | Goldman | |
| 4/16/2024 | Sell → Hold | Deutsche Bank | ||
| 2/8/2024 | Hold → Sell | Deutsche Bank | ||
| 1/23/2024 | $85.00 | Overweight | Morgan Stanley | |
| 1/16/2024 | Sell | UBS |
First and only AKT inhibitor combination to demonstrate benefit in this specific subtype of prostate cancer Positive high-level results from the CAPItello-281 Phase III trial showed that AstraZeneca's TRUQAP® (capivasertib) in combination with abiraterone and androgen deprivation therapy (ADT) demonstrated a statistically significant and clinically meaningful improvement in the primary endpoint of radiographic progression-free survival (rPFS) versus abiraterone and ADT with placebo in patients with PTEN-deficient de novo metastatic hormone-sensitive prostate cancer (mHSPC). Overall survival (OS) data were immature at the time of this analysis; however, the TRUQAP combination showed an e
US ACT on Health Equity contributions support AstraZeneca's long-term ambition in health equity and total more than $15 million to date AstraZeneca today pledged $3.5 million to nonprofit organizations across the US as part of Accelerate Change Together (ACT) on Health Equity, an initiative to improve access, affordability and outcomes for patients in urban, suburban and rural communities. This brings the total contributions from the program to more than $15 million to date. Now in its fourth year, ACT on Health Equity will fund 53 nonprofit programs which aim to improve access to healthcare, address housing and nutrition as social determinants of health, advance culturally competent ch
MENLO PARK, Calif., Nov. 18, 2024 /PRNewswire/ -- GRAIL, Inc. (NASDAQ:GRAL), a healthcare company whose mission is to detect cancer early when it can be cured, today announced that the first patient has been tested for eligibility with the investigational GRAIL Non-Small Cell Lung Cancer (NSCLC) ctDNA Assay in the global TROPION-Lung12 Phase 3 study evaluating adjuvant treatment regimens in patients with Stage I adenocarcinoma NSCLC. The study is sponsored by AstraZeneca (NASDAQ:AZN) in collaboration with Daiichi Sankyo (TSE: 4568). The study, which is being conducted under a
4 - Fusion Pharmaceuticals Inc. (0001805890) (Issuer)
4 - Fusion Pharmaceuticals Inc. (0001805890) (Issuer)
4 - Fusion Pharmaceuticals Inc. (0001805890) (Issuer)
SC 13G/A - Fusion Pharmaceuticals Inc. (0001805890) (Subject)
SC 13D - Fusion Pharmaceuticals Inc. (0001805890) (Subject)
SC 13D/A - Fusion Pharmaceuticals Inc. (0001805890) (Subject)
6-K - ASTRAZENECA PLC (0000901832) (Filer)
6-K - ASTRAZENECA PLC (0000901832) (Filer)
6-K - ASTRAZENECA PLC (0000901832) (Filer)
UBS upgraded AstraZeneca from Sell to Neutral
Deutsche Bank upgraded AstraZeneca from Sell to Hold
Deutsche Bank downgraded AstraZeneca from Hold to Sell
On Thursday, AstraZeneca Plc (NASDAQ:AZN) reported second-quarter sales of $12.94 billion, up 13% year over year (+17% at constant currency), beating the consensus of $12.75 billion. The company’s adjusted EPADS reached $0.99, inline with consensus. The adjusted EPS was $1.98 (1 ADR = 2 Common Shares) Also Read: China Approves AstraZeneca’s Tagrisso-Chemotherapy Combo Regime For Previously Untreated Lung Cancer Patients. AstraZeneca’s top business, oncology, delivered a 15% jump (up 19% on constant currency) in second-quarter sales to $5.33 billion. Tagrisso, Imfinzi, and Calquence were the top-selling cancer drugs, generating $1.61 billion, $1.15 billion, and $790 million, res
AstraZeneca (NASDAQ:AZN) reported quarterly adjsuted earnings of $0.99 per share which missed the analyst consensus estimate of $1.20 by 17.5 percent. This is a 7.91 percent decrease over earnings of $1.07 per share from<p>AstraZeneca (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AZN#NASDAQ">AZN</a>) reported quarterly adjsuted earnings of $0.99 per share which missed the analyst consensus estimate of $1.20 by 17.5 percent. This is a 7.91 percent decrease over earnings of $1.07 per share from the same period last year. The company reported quarterly sales of $12.98 billion which beat the analyst consensus estimate of $12.75 billion by 1.83 percent. This is a 13.73 percent in
ROCKVILLE, Md., June 6, 2024 /PRNewswire/ -- I-Mab (NASDAQ:IMAB) (the "Company"), a U.S.-based, global biotech company, exclusively focused on the development and potential commercialization of highly differentiated immunotherapies for the treatment of cancer, today announced the appointment of Dr. Phillip Dennis as Chief Medical Officer. Dr. Dennis, who will join I-Mab effective June 17, 2024, will lead the Company's global clinical development efforts and serve as a member of I-Mab's Executive Leadership Team. "I am pleased to welcome Dr. Phillip Dennis as our Chief Medical
In recognition of Rare Disease Day on February 29, Alexion welcomes people across the country to join the international colourUp4RARE challenge and learn more about the impact of rare diseases on an estimated three million Canadian families MISSISSAUGA, ON, Feb. 26, 2024 /CNW/ - Alexion Pharma Canada Corp., AstraZeneca's Rare Disease group, is marking Rare Disease Day on February 29 by launching colourUp4RARE. The international campaign aims to raise awareness of how to improve quality of life of people living with rare diseases in Canada, and around the world. Approximately,
NIH data show that globally less than 2% of genetic information being studied today originates from people of African ancestry1 The newly established Diaspora Human Genomics Institute (DHGI) will manage the Together for CHANGE initiative, which aims to increase available genomic data for people of African ancestry and enhance representation in STEM careers NASHVILLE, Tenn. and TARRYTOWN, N.Y. and WILMINGTON, Del. and BAGSVAERD, Denmark and BASEL, Switzerland, Oct. 18, 2023 (GLOBE NEWSWIRE) -- Meharry Medical College, along with partners Regeneron Genetics Center® (RGC™), AstraZeneca, Novo Nordisk, and Roche, today announced the launch of the Together for CHANGE™ ("Changing Healthcare for
Upgrade to full year 2024 guidance underpinned by strong underlying growth momentum AstraZeneca: Revenue and EPS summary 9M 2024 % Change Q3 2024 % Change $m Actual CER1 $m Actual CER - Product Sales 37,576 16 19 12,947 18 20 - Alliance Revenue 1,498 49 50 559 48 50 - Collaboration Revenue 108 (66) (66) 59 (39) (40) Total Revenue 39,182 16 19 13,565 18 21 Reported EPS $3.57 11 21
ODD and RPDD granted by the FDA and ODD granted by the European Commission to UCART22 for the treatment of ALLODD granted by the FDA to CLLS52 (alemtuzumab) for ALL treatmentCash position of $273 million as of June 30, 20241; cash runway projection into 2026 NEW YORK, Aug. 06, 2024 (GLOBE NEWSWIRE) -- Cellectis (the "Company") (NASDAQ:CLLS), a clinical-stage biotechnology company using its pioneering gene editing platform to develop life-saving cell and gene therapies, today provided business updates and reported financial results for the six-month period ending June 30, 2024. "Over the past months, we have achieved a significant milestone with the granting of ODD designations by
Strong underlying growth supports FY 2024 guidance upgrade, with both Total Revenue and Core EPS now expected to increase by a mid teens percentage at CER1 AstraZeneca: Revenue and EPS summary H1 2024 % Change Q2 2024 % Change $m Actual CER $m Actual CER - Product Sales 24,629 15 18 12,452 14 18 - Alliance Revenue 939 50 50 482 42 42 - Collaboration Revenue 49 (78) (78) 4 (98) (98) Total Revenue 25,617 15 18 12,938 13 17